324789-64-2

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 324788-99-0 5-(R)-hydroxymethyl-3-[4'-tert-butoxycarbonyl-3'-fluorophenyl]oxazolidine-2-one 
• 140373-77-9 tert-butyl 2-fluoro-4-aminobenzoate 
• 403-23-6 2-fluoro-4-nitrobenzoyl chloride 
• 1427-07-2 2-fluoro-4-nitrotoluene 

Downstream Products

• 324789-00-6 tert-butyl 4-(5-azidomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-benzoate 
• 232951-33-6 5-(S)-(N-Acetylaminomethyl)-3-[4'-(tert-butoxy)carbonyl-3'-fluorophenyl]-oxazolidine-2-one 
• 232950-93-5 5-(S)-acetamidomethyl-3-[4'-(pentafluorophenyl)oxycarbonyl-3'-fluorophenyl]-oxazolidine-2-one 
• 1087352-59-7 tert-butyl {3-[3-fluoro-4-(4-imidazol-1-ylmethyl-thiazol-2-yl)-phenyl]-2-oxo-oxazolidin-5(S)-ylmethyl}-carbamate 
• 1087352-87-1 methyl {3-[3-fluoro-4-(4-imidazol-1-ylmethyl-thiazol-2-yl)-phenyl]-2-oxo-oxazolidin-5(S)-ylmethyl}-carbamate 
• 1087353-05-6 O-methyl {3-[3-fluoro-4-(4-imidazol-1-ylmethyl-thiazol-2-yl)-phenyl]-2-oxo-oxazolidin-5(S)-ylmethyl}-thiocarbamate 
• 1087353-76-1 tert-butyl {3-[4-(4-chloromethyl-thiazol-2-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5(S)-ylmethyl}-carbamate 
• 1087352-62-2 N-{3-[3-fluoro-4-(4-imidazol-1-ylmethyl-thiazol-2-yl)-phenyl]-2-oxo-oxazolidin-5(S)-ylmethyl}-acetamide 
• 1087353-14-7 N-{3-[3-fluoro-4-(4-imidazol-1-ylmethyl-thiazol-2-yl)-phenyl]-2-oxo-oxazolidin-5(S)-ylmethyl}-thioacetamide 
• 1087353-74-9 tert-butyl [3-(4-carbamoyl-3-fluoro-phenyl)-2-oxo-oxazolidin-5(S)-ylmethyl]-carbamate 
• 1087353-75-0 tert-butyl [3-(3-fluoro-4-thiocarbamoyl-phenyI)-2-oxo-oxazolidin-5(S)-ylmethyl]-carbamate 
• 324789-26-6 4-(5-azidomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-benzamide 
• 324789-28-8 5-(S)-aminomethyl-3-[4'-aminocarbonyl-3'-fluorophenyl]oxazolidine-2-one 
• 232950-92-4 5-(S)-Acetamidomethyl-3-[4'-carboxy-3'-fluorophenyl]-oxazolidine-2-one 

Relevant academic research and scientific papers

NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS

The present invention relates to novel oxazolidinone compounds of formula (I) with antibacterial activity, their pharmaceutically acceptable salts, their stereoisomers, their prodrugs, pharmaceutical compositions comprising the same and to their use as therapeutic agents

Novel oxazolidinone-quinolone hybrid antimicrobials

Antimicrobial compounds incorporating oxazolidinone and quinolone pharmacophore substructures have been synthesized and evaluated. Representative analogues 2, 5, and 6 display an improved potency versus linezolid against gram-positive and fastidious gram-negative pathogens. The compounds are also active against linezolid- and ciprofloxacin-resistant Staphylococcus aureus and Enterococcus faecium strains. The MOA for these new antimicrobials is consistent with a combination of protein synthesis and gyrase A/topoisomerase IV inhibition, with a structure-dependent degree of the contribution from each inhibitory mechanism.